

### REMARKS

This amendment addresses the official Action of April 13, 2006, 2006. The claims remaining in the case are 1-6 and newly added claim 12 (support found on page 21 of the specification). Claims 7-11 have been withdrawn without prejudice to refile.

Claims 1 and 6 have been amended to reflect Applicant's selection of Group III pursuant to the examiner's 2/17/06 restriction requirement.

Claim 1 is rejected under 35 USC 102(b) as being anticipated by Kubodera et al., because it discloses two compounds that fall within the scope of claim 1. Claim 1 has been amended to recite that R<sup>2</sup> cannot be butyl thereby overcoming the examiner's concerns.

Claim 1 is rejected under 35 USC 103(a) as unpatentable over Kubodera et al. The examiner states that the claimed invention teaches a compound or a pharmaceutical formulation for the treatment of disease such as Alzheimer's. To the contrary, the claimed invention is directed to the use of compounds of claim 1 to treat glaucoma and/or bone disorders. There is no discussion of Alzheimer's disease. Additionally, is no mention of the claimed compounds in Kubodera et al. Therefore, one of ordinary skill in the art would not have appreciated the use of the compounds of the claimed invention based upon Alzheimer's disease.

The examiner rejects claim 13 under 35 USC 101 because of the claimed recitation of "use". However, Applicants are not aware of a claim 13. The instantly claimed invention consists of a total of 11 claims until this correspondence when claim 12 was added.

Claim 15 is objected to. As indicated with claim 13, the claimed invention does not contain a claim 15.

Claims 1-6 and 12-15 are objected to for being dependent upon a rejected base claim. Claim 1 has been amended to overcome the examiner's rejections under 102(b) and 103(a). Accordingly, Applicant's believe claim 1 is now in condition for allowance.

Claims 2-6 are objected to as containing non-elected subject matter. The claims have been amended herein to overcome this concern of the examiner.

The examiner requests that the abstract of the invention be presented on a separate page. Attached is the abstract on a separate page.

As a result of the herein amendments and remarks Applicant's believe the examiner's concerns have been met and overcome. The Examiner is therefore respectfully requested to remove the objections and rejections.

Respectfully submitted,

By: 

Sylvia A. Ayler

Reg. No. 36,436

Attorney for Applicant(s)

MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-4909

Date: May 1, 2006